Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.8K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Drug Therapy01:28

Drug Therapy

333
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
333
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of combined cerebellar tACS-iTBS in individuals with ataxia (EtABeta): a crossover investigation.

Trials·2026
Same author

Exoskeleton-Assisted Therapy Enhances Upper Limb Motor Recovery in Early Subacute Stroke: A Multicenter, Single-Blind Randomized Controlled Trial.

Stroke·2026
Same author

The Role of Functional Electrical Stimulation in Stroke Rehabilitation: A Preliminary Study.

Physiotherapy research international : the journal for researchers and clinicians in physical therapy·2025
Same author

Tailoring robot-assisted arm training to individuals with stroke: bridging neuroscience principles and clinical practice.

Frontiers in neurology·2025
Same author

Association of TMS-EEG interhemispheric imbalance with upper limb motor impairment in chronic stroke patients: An exploratory study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025
Same author

Robot-Assisted Therapy in Guillain-Barrè Syndrome: Systematic Review of Primary Evidence and Study Protocol for a Randomized Clinical Trial.

Journal of clinical medicine·2024

Related Experiment Video

Updated: Mar 2, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

10.9K

Advances in antidepressants for treating post-stroke depression.

Stefano Paolucci1

  • 1a Department of Neurorehabilitation , Fondazione I.R.C.C.S. Santa Lucia , Rome , Italy.

Expert Opinion on Pharmacotherapy
|May 24, 2017
PubMed
Summary

Post-stroke depression (PSD) affects many survivors, impacting recovery and quality of life. Antidepressant treatment shows promise but requires more research for optimal drug choice and duration.

Keywords:
Depressionantidepressantsfunctional outcomerehabilitationstroke

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

677
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.6K

Related Experiment Videos

Last Updated: Mar 2, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

10.9K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

677
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Post-stroke depression (PSD) is a prevalent complication affecting nearly one-third of stroke survivors.
  • PSD significantly impacts mortality, functional outcomes, rehabilitation, and quality of life.
  • Current clinical practice undertreats a majority of patients experiencing PSD.

Purpose of the Study:

  • To provide an updated review of the pharmacological treatment of PSD.
  • To examine the efficacy, safety, and role of antidepressants in PSD prevention and treatment.
  • To explore the potential of antidepressants in improving functional recovery after stroke.

Main Methods:

  • Literature review of scientific reports on antidepressants for PSD.
  • Analysis of current data on the efficacy and safety of various antidepressant classes.
  • Discussion of emerging evidence, including newer agents like vortioxetine.

Main Results:

  • Antidepressant treatment can alleviate depressive symptoms in PSD.
  • Selective serotonin reuptical inhibitors (SSRIs) are often preferred due to safety profiles.
  • Ongoing debate exists regarding SSRI use and potential mortality risks.
  • The optimal antidepressant and treatment duration for PSD remain unidentified.

Conclusions:

  • Pharmacological treatment is crucial for managing PSD symptoms.
  • Further research is needed to establish optimal antidepressant strategies for PSD.
  • Newer antidepressants, such as vortioxetine, show potential for cognitive enhancement in PSD, warranting further investigation.